Photo by solenfeyissa from unsplash
In their prospective, randomized, placebo-controlled, double-blind trial that investigated anti-fracture efficacy of zoledronate in a total of 2000 osteopenic postmenopausal women aged over 65 years, Reid et al. [1, 2] provides… Click to show full abstract
In their prospective, randomized, placebo-controlled, double-blind trial that investigated anti-fracture efficacy of zoledronate in a total of 2000 osteopenic postmenopausal women aged over 65 years, Reid et al. [1, 2] provides crucial evidence that is highly useful for clinical practice; intravenous administration of zoledronate at a dose of 5 mg every 18 months for 6 years reduced fracture risk independently of baseline clinical characteristics including age, dietary calcium intake, and recent falls history. This article is protected by copyright. All rights reserved.
Journal Title: Journal of Internal Medicine
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!